BMO Downgrades Zoetis After Valeant Report

Loading...
Loading...
In a report published Friday, BMO Capital analyst Alex Arfaei downgraded the rating on
Zoetis IncZTS
from Outperform to Market Perform, while raising the price target from $51 to $57, following the almost 29 percent increase in the share price year-to-date. The analyst believes that the company could be acquired for about $60 per share, representing about 8 percent upside to the stock's closing price on Thursday. However, in the absence of the takeout premium, the share price could fall as much as 15-20 percent. "We believe it would be very difficult for ZTS management to argue that they could generate similar near-term value for ZTS shareholders, especially after their recently announced operational efficiency initiative. This should support the prospects for a potential deal, in our view," Arfaei stated. The analyst believes that there is a high probability of Zoetis being acquired. The company has a productive R&D division, with new drugs like Apoquel, which are promising. "Therefore, ZTS, as the best-in-class animal health company, unquestionably deserves a premium, in our view," Arfaei added.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsAlex ArfaeiBMO Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...